Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMYMP) EBT (2016 - 2025)

Historic EBT for Bristol Myers Squibb (BMYMP) over the last 17 years, with Q4 2025 value amounting to $1.5 billion.

  • Bristol Myers Squibb's EBT rose 74000.0% to $1.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $9.3 billion, marking a year-over-year increase of 21132.59%. This contributed to the annual value of $9.3 billion for FY2025, which is 21132.59% up from last year.
  • Bristol Myers Squibb's EBT amounted to $1.5 billion in Q4 2025, which was up 74000.0% from $3.1 billion recorded in Q3 2025.
  • In the past 5 years, Bristol Myers Squibb's EBT registered a high of $3.1 billion during Q3 2025, and its lowest value of -$11.5 billion during Q1 2024.
  • Over the past 5 years, Bristol Myers Squibb's median EBT value was $1.9 billion (recorded in 2021), while the average stood at $1.3 billion.
  • In the last 5 years, Bristol Myers Squibb's EBT skyrocketed by 93223.68% in 2021 and then tumbled by 51574.01% in 2024.
  • Bristol Myers Squibb's EBT (Quarter) stood at $1.9 billion in 2021, then grew by 0.05% to $1.9 billion in 2022, then decreased by 9.95% to $1.7 billion in 2023, then crashed by 89.55% to $175.0 million in 2024, then surged by 740.0% to $1.5 billion in 2025.
  • Its last three reported values are $1.5 billion in Q4 2025, $3.1 billion for Q3 2025, and $1.8 billion during Q2 2025.